Literature DB >> 22945227

Treatment of chemotherapy-refractory cancer in the advanced therapy access program.

Akseli Hemminki.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22945227      PMCID： PMC3437585          DOI： 10.1038/mt.2012.170

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  10 in total

1.  Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.

Authors:  Sari Pesonen; Iulia Diaconu; Vincenzo Cerullo; Sophie Escutenaire; Mari Raki; Lotta Kangasniemi; Petri Nokisalmi; Gianpietro Dotti; Kilian Guse; Leena Laasonen; Kaarina Partanen; Eerika Karli; Elina Haavisto; Minna Oksanen; Aila Karioja-Kallio; Päivi Hannuksela; Sirkka-Liisa Holm; Satu Kauppinen; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Int J Cancer       Date:  2011-08-08       Impact factor: 7.396

2.  Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors.

Authors:  Petri Nokisalmi; Sari Pesonen; Sophie Escutenaire; Merja Särkioja; Mari Raki; Vincenzo Cerullo; Leena Laasonen; Ramon Alemany; Juan Rojas; Manel Cascallo; Kilian Guse; Maria Rajecki; Lotta Kangasniemi; Elina Haavisto; Aila Karioja-Kallio; Päivi Hannuksela; Minna Oksanen; Anna Kanerva; Timo Joensuu; Laura Ahtiainen; Akseli Hemminki
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

3.  Differing approaches to experimental therapeutics: are we a world apart?

Authors:  Timothy P Cripe
Journal:  Mol Ther       Date:  2012-09       Impact factor: 11.454

4.  Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.

Authors:  Vincenzo Cerullo; Iulia Diaconu; Lotta Kangasniemi; Maria Rajecki; Sophie Escutenaire; Anniina Koski; Valentina Romano; Noora Rouvinen; Tamara Tuuminen; Leena Laasonen; Kaarina Partanen; Satu Kauppinen; Timo Joensuu; Minna Oksanen; Sirkka-Liisa Holm; Elina Haavisto; Aila Karioja-Kallio; Anna Kanerva; Sari Pesonen; Petteri T Arstila; Akseli Hemminki
Journal:  Mol Ther       Date:  2011-06-14       Impact factor: 11.454

5.  Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.

Authors:  Vincenzo Cerullo; Sari Pesonen; Iulia Diaconu; Sophie Escutenaire; Petteri T Arstila; Matteo Ugolini; Petri Nokisalmi; Mari Raki; Leena Laasonen; Merja Särkioja; Maria Rajecki; Lotta Kangasniemi; Kilian Guse; Andreas Helminen; Laura Ahtiainen; Ari Ristimäki; Anne Räisänen-Sokolowski; Elina Haavisto; Minna Oksanen; Eerika Karli; Aila Karioja-Kallio; Sirkka-Liisa Holm; Mauri Kouri; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

6.  Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors.

Authors:  S Pesonen; P Nokisalmi; S Escutenaire; M Särkioja; M Raki; V Cerullo; L Kangasniemi; L Laasonen; C Ribacka; K Guse; E Haavisto; M Oksanen; M Rajecki; A Helminen; A Ristimäki; A Karioja-Kallio; E Karli; T Kantola; G Bauerschmitz; A Kanerva; T Joensuu; A Hemminki
Journal:  Gene Ther       Date:  2010-03-18       Impact factor: 5.250

7.  Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer.

Authors:  Anniina Koski; Mari Raki; Petri Nokisalmi; Ilkka Liikanen; Lotta Kangasniemi; Timo Joensuu; Anna Kanerva; Sari Pesonen; Ramon Alemany; Akseli Hemminki
Journal:  Mol Ther       Date:  2011-11-01       Impact factor: 11.454

8.  Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.

Authors:  Otto Hemminki; Iulia Diaconu; Vincenzo Cerullo; Saila K Pesonen; Anna Kanerva; Timo Joensuu; Kalevi Kairemo; Leena Laasonen; Kaarina Partanen; Lotta Kangasniemi; Andre Lieber; Sari Pesonen; Akseli Hemminki
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

9.  Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients.

Authors:  Sari Pesonen; Iulia Diaconu; Lotta Kangasniemi; Tuuli Ranki; Anna Kanerva; Saila K Pesonen; Ulrike Gerdemann; Ann M Leen; Kalevi Kairemo; Minna Oksanen; Elina Haavisto; Sirkka-Liisa Holm; Aila Karioja-Kallio; Satu Kauppinen; Kaarina P L Partanen; Leena Laasonen; Tima Joensuu; Tuomo Alanko; Vincenzo Cerullo; Akseli Hemminki
Journal:  Cancer Res       Date:  2012-02-09       Impact factor: 12.701

10.  Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

Authors:  Anniina Koski; Lotta Kangasniemi; Sophie Escutenaire; Sari Pesonen; Vincenzo Cerullo; Iulia Diaconu; Petri Nokisalmi; Mari Raki; Maria Rajecki; Kilian Guse; Tuuli Ranki; Minna Oksanen; Sirkka-Liisa Holm; Elina Haavisto; Aila Karioja-Kallio; Leena Laasonen; Kaarina Partanen; Matteo Ugolini; Andreas Helminen; Eerika Karli; Päivi Hannuksela; Saila Pesonen; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2010-07-27       Impact factor: 11.454
  10 in total
  4 in total

1.  Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.

Authors:  Anniina Koski; Simona Bramante; Anja Kipar; Minna Oksanen; Juuso Juhila; Lotta Vassilev; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2015-07-09       Impact factor: 11.454

2.  Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer.

Authors:  Simona Bramante; Anniina Koski; Ilkka Liikanen; Lotta Vassilev; Minna Oksanen; Mikko Siurala; Raita Heiskanen; Tiina Hakonen; Timo Joensuu; Anna Kanerva; Sari Pesonen; Akseli Hemminki
Journal:  Oncoimmunology       Date:  2015-08-27       Impact factor: 8.110

3.  "Special exemptions": should they be put on trial?

Authors:  H Bobby Gaspar; Sue Swift; Adrian J Thrasher
Journal:  Mol Ther       Date:  2013-02       Impact factor: 11.454

4.  Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.

Authors:  Otto Hemminki; Suvi Parviainen; Juuso Juhila; Riku Turkki; Nina Linder; Johan Lundin; Matti Kankainen; Ari Ristimäki; Anniina Koski; Ilkka Liikanen; Minna Oksanen; Dirk M Nettelbeck; Kalevi Kairemo; Kaarina Partanen; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Oncotarget       Date:  2015-02-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.